UB Paderborn / Katalog / Suche / in CDI

1 – 19 von 19

Sortiert nach

PCV37 BUDGET IMPACT ANALYSIS OF ANTIPLATELET THERAPY WITH CANGRELOR IN PATIENTS WITH ACUTE CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SPAIN

Value in health, 2019-11, Vol.22, p.S547

2019

Volltextzugriff (PDF)

A new case of hereditary histidine-rich glycoprotein deficiency with familial thrombophilia

Thrombosis and haemostasis, 1996, Vol.75 (2), p.374

1996

Volltextzugriff (PDF)

Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses

Blood coagulation & fibrinolysis, 1998-01, Vol.9 (2), p.137-142

1998

Volltextzugriff (PDF)

PS levels are not influenced by the endogenous estradiol concentration

Thrombosis and haemostasis, 1996-07, Vol.76 (1), p.124

1996

Volltextzugriff (PDF)

The influence of low protein s plasma levels in young women, on the definition of normal range

Thrombosis research, 1994-01, Vol.73 (2), p.149-152

1994

Volltextzugriff (PDF)

The Accurate Definition of Protein S Deficiency May Avoid the Misestimation of the Frequency of This Defect

Blood, 1996-03, Vol.87 (6), p.2604-2604

1996

Volltextzugriff (PDF)

Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophilia

Thrombosis research, 1995-12, Vol.80 (5), p.413-418

1995

Volltextzugriff (PDF)

Kinetic behaviour of the TFPI and anti-FXa effects, after the injection of a LMWH (RO-11) in healthy subjects

Thrombosis and haemostasis, 1995-04, Vol.73 (4), p.728

1995

Volltextzugriff (PDF)

The effect of endogenous oestradiol levels on protein S concentration during a menstrual cycle and after GnRH analogues and gonadotropin therapy

British journal of haematology, 1995-06, Vol.90 (2), p.438-441

1995

Volltextzugriff (PDF)

Familial elevation of plasma histidine-rich glycoprotein. A case associated with recurrent venous thrombosis and high PAI-1 levels

Thrombosis research, 1992-05, Vol.66 (2), p.265-270

1992

Volltextzugriff (PDF)

The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis

Blood coagulation & fibrinolysis, 1992-02, Vol.3 (1), p.33-38

1992

Volltextzugriff (PDF)

Fibrinolytic abnormalities. A Spanish multicenter study ebt.I on 443 patients with venous thromboembolic disease

Thrombosis research, 1992-05, Vol.66 (4), p.455-460

1992

Volltextzugriff (PDF)

Detection of two new polymorphisms by PCR-SSCP analysis of the histidine-rich glycoprotein gene in three families with abnormal plasma HRG levels

Fibrinolysis & proteolysis, 1997-09, Vol.11 (5), p.279-285

1997

Volltextzugriff (PDF)

Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers--a dose-finding study within the therapeutical range

Thrombosis and haemostasis, 1997-01, Vol.77 (1), p.133

1997

Volltextzugriff (PDF)

Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11)—A three way cross-over study in healthy volunteers

Thrombosis research, 1995-04, Vol.78 (1), p.77-86

1995

Volltextzugriff (PDF)

In-Vitro and Ex-Vivo Neutralizing Effect of Protamine Sulphate on the Anticoagulant Activity of a New Low Molecular Mass Heparin

Thrombosis research, 1998-01, Vol.89 (2), p.79-83

1998

Volltextzugriff (PDF)

The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stastis

Blood coagulation & fibrinolysis, 1992, Vol.3 (1), p.33-38

1992

Volltextzugriff (PDF)

Fibrinolytic abnormalities. A Spanish multicenter study ebt. I: On 443 patients with venous thromboembolic disease

Thrombosis research, 1992-05, Vol.66 (4), p.455-460

1992

Volltextzugriff (PDF)

Factores predictivos del riesgo de enfermedad cardiovascular en los pacientes con diabetes tipo 2 e hipercolesterolemia. Estudio ESODIAH

Revista española de cardiologia, 2007, Vol.60 (3), p.251-258

2007

Volltextzugriff (PDF)

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(19)

Sprache

Englisch
(18)
Spanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PCV37 BUDGET IMPACT ANALYSIS OF ANTIPLATELET THERAPY WITH CANGRELOR IN PATIENTS WITH ACUTE CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN SPAIN

A new case of hereditary histidine-rich glycoprotein deficiency with familial thrombophilia

Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses

PS levels are not influenced by the endogenous estradiol concentration

The influence of low protein s plasma levels in young women, on the definition of normal range

The Accurate Definition of Protein S Deficiency May Avoid the Misestimation of the Frequency of This Defect

Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophilia

Kinetic behaviour of the TFPI and anti-FXa effects, after the injection of a LMWH (RO-11) in healthy subjects

The effect of endogenous oestradiol levels on protein S concentration during a menstrual cycle and after GnRH analogues and gonadotropin therapy

Familial elevation of plasma histidine-rich glycoprotein. A case associated with recurrent venous thrombosis and high PAI-1 levels

The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis

Fibrinolytic abnormalities. A Spanish multicenter study ebt.I on 443 patients with venous thromboembolic disease

Detection of two new polymorphisms by PCR-SSCP analysis of the histidine-rich glycoprotein gene in three families with abnormal plasma HRG levels

Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers--a dose-finding study within the therapeutical range

Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11)—A three way cross-over study in healthy volunteers

In-Vitro and Ex-Vivo Neutralizing Effect of Protamine Sulphate on the Anticoagulant Activity of a New Low Molecular Mass Heparin

The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stastis

Fibrinolytic abnormalities. A Spanish multicenter study ebt. I: On 443 patients with venous thromboembolic disease

Factores predictivos del riesgo de enfermedad cardiovascular en los pacientes con diabetes tipo 2 e hipercolesterolemia. Estudio ESODIAH

Suchergebnisse filtern